指南与共识基础与转化研究流行病学与生物统计临床试验与 GCP

脓毒症与危重症的共识性免疫失调框架

A consensus immune dysregulation framework for sepsis and critical illnesses.
指南 / 共识 · Nat Med · 2025-09-30

SUBSPACE国际联盟分析37个独立队列逾7074份样本,构建细胞类型特异性基因表达特征以量化免疫区室失调。髓系和淋系失调与疾病严重程度及死亡相关,并在ARDS、创伤和烧伤中同样存在。随机对照试验分析显示,上述失调与阿那白滞素、皮质类固醇治疗患者的差异性死亡相关。

要点

  • 髓系和淋系失调与危重症疾病严重程度及死亡相关。
  • 该失调在脓毒症、ARDS、创伤和烧伤中均可见,提示保守机制。
  • 失调与阿那白滞素及皮质类固醇治疗患者的差异性死亡相关。

核心结论

  • 所提出的基于免疫学的细胞区室失调量化框架,可能为理解危重症免疫失调提供有预后和治疗价值的工具。

研究设计与样本

  • SUBSPACE联盟是一项通过共享转录组数据推进危重症精准医学的国际联盟。

主要发现

  • 在37个独立队列逾7074份样本中评估脓毒症现有免疫内型的重叠,并开发细胞类型特异性基因表达特征以量化免疫区室失调。
  • 髓系和淋系失调在所有队列中均与疾病严重程度和死亡相关。
  • 该失调也见于ARDS、创伤和烧伤患者,提示在不同危重症综合征间存在保守机制。
  • 随机对照试验数据分析显示,髓系和淋系失调与SAVE-MORE试验(n=452)中接受阿那白滞素治疗患者的差异性死亡相关,并与VICTAS(n=89)和VANISH(n=117)试验中接受皮质类固醇治疗患者的差异性死亡相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Critical care syndromes such as sepsis, acute respiratory distress syndrome (ARDS) and trauma continue to have unacceptably high morbidity and mortality, with progress limited by the inherent heterogeneity within syndromic illnesses. Although numerous immune endotypes have been proposed for sepsis and critical care, the similarities and differences between these endotypes remain unclear, hindering clinical translation. The SUBSPACE consortium is an international consortium that aims to advance precision medicine in critical care through the sharing of transcriptomic data. Here, evaluating the overlap of existing immune endotypes in sepsis across >7,074 samples from 37 independent cohorts, we developed cell-type-specific gene expression signatures to quantify dysregulation within immune compartments. Myeloid and lymphoid dysregulation were associated with disease severity and mortality across all cohorts. Importantly, this dysregulation was also observed in patients with ARDS, trauma and burns, suggesting a conserved mechanism across various critical illness syndromes. Moreover, analysis of randomized controlled trial data revealed that myeloid and lymphoid dysregulation are associated with differential mortality in patients treated with anakinra in the SAVE-MORE trial (n = 452) and corticosteroids in the VICTAS (n = 89) and VANISH (n = 117) trials, underscoring their prognostic and therapeutic implications. In conclusion, our proposed immunology-based framework for quantifying cellular compartment dysregulation offers a potentially valuable tool for understanding immune dysregulation in critical illness with prognostic and therapeutic significance.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Moore AR, Zheng H, Ganesan A, et al. A consensus immune dysregulation framework for sepsis and critical illnesses. Nat Med. 2025. PMID: 41028543. doi:10.1038/s41591-025-03956-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。